Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting.

[1]  J. Maroto,et al.  Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine/cisplatin as first-line therapy for locally advanced or metastatic bladder cancer: Phase Ib results. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Roychoudhury,et al.  Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. , 2012, Urology.

[3]  S. Groshen,et al.  Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Dimopoulos,et al.  Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Bochner,et al.  Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Millikan,et al.  Can we reliably identify patients for radical cystectomy without neoadjuvant chemotherapy? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Boorjian,et al.  Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy , 2011, BJU international.

[8]  A. Kibel.  International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial , 2011 .

[9]  V. Guillem,et al.  Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Grossman,et al.  Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy , 2009, Cancer.

[11]  David C. Smith,et al.  A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). , 2009, The Journal of urology.

[12]  E. Klein,et al.  Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder , 2009, Cancer.

[13]  H. Grossman,et al.  Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. , 2009, Urology.

[14]  M. Milowsky,et al.  Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. , 2009, European urology.

[15]  P. Russo,et al.  A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder , 2008, Cancer.

[16]  H. Herr.  Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. , 2008, European urology.

[17]  G. Muto,et al.  Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial , 2008 .

[18]  D. Amadori,et al.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.

[19]  E. Wallen,et al.  Comparison of the clinical and pathologic staging in patients undergoing radical cystectomy for bladder cancer. , 2007, International braz j urol : official journal of the Brazilian Society of Urology.

[20]  A. Vickers,et al.  Standardization of pelvic lymphadenectomy performed at radical cystectomy , 2006, Cancer.

[21]  A. Vickers,et al.  Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder , 2006, Cancer.

[22]  L. Collette,et al.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.

[23]  Y. Lotan,et al.  Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[25]  M. Parmar,et al.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. , 2005, European urology.

[26]  V. Ficarra,et al.  Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma , 2005, BJU international.

[27]  N. Masumori,et al.  Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. , 2004, Urology.

[28]  N. James,et al.  A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer , 2004, British Journal of Cancer.

[29]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[31]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[32]  R. Millikan,et al.  Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? , 2003, The Journal of urology.

[33]  C. Sternberg,et al.  Can patient selection for bladder preservation be based on response to chemotherapy? , 2003, Cancer.

[34]  Badrinath R Konety,et al.  Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. , 2003, The Journal of urology.

[35]  H. Wolf,et al.  Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. , 2003, The Journal of urology.

[36]  F. Burkhard,et al.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  V. Reuter,et al.  Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. , 2003, The Journal of urology.

[38]  M. Droller.  Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. , 2002, The Journal of urology.

[39]  H. Miyake,et al.  Prognostic variables in patients who have undergone radical cystectomy for transitional cell carcinoma of the bladder. , 2001, Japanese journal of clinical oncology.

[40]  P. Russo,et al.  Cystectomy for bladder cancer: a contemporary series. , 2001, The Journal of urology.

[41]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Benson,et al.  The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer. , 2000, The Journal of urology.

[44]  J. Thüroff,et al.  Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis , 2000, BJU international.

[45]  H. Grossman,et al.  A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. , 1999, The Journal of urology.

[46]  G. Griffiths.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists , 1999 .

[47]  P. Bassi,et al.  Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. , 1999, The Journal of urology.

[48]  S. Lerner.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. , 1999, Lancet.

[49]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[50]  A. Ribas,et al.  Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma , 1997, Cancer.

[51]  M. Ghoneim,et al.  Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. , 1997, The Journal of urology.

[52]  H. Herr.  Uncertainty and outcome of invasive bladder tumors. , 1996, Urologic oncology.

[53]  F. Freiha,et al.  A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. , 1996, The Journal of urology.

[54]  S. Mondillo,et al.  Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study , 1996, Cancer.

[55]  H. Scher,et al.  Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Stöckle,et al.  Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. , 1995, The Journal of urology.

[57]  L. Mazzucchelli,et al.  Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. , 1994, The Journal of urology.

[58]  N. Vogelzang,et al.  The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group. , 1992, The Journal of urology.

[59]  Wishnow Ki,et al.  Will Rogers and the results of radical cystectomy for invasive bladder cancer. , 1991 .

[60]  P. Bassi,et al.  Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. , 1991, The Journal of urology.

[61]  K. Wishnow,et al.  Will Rogers and the results of radical cystectomy for invasive bladder cancer. , 1991, The Urologic clinics of North America.

[62]  S. Groshen,et al.  Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. , 1990, Seminars in urology.

[63]  A. Bono,et al.  Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. , 1989, Progress in clinical and biological research.